Nathan Merrill

Nathan Merrill

Auto-generated profile, based on publicly available information

Nathan Merrill

University of Michigan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2024 in European Urology
Verified
Journal Article
Closed access
NMNathan M. Merrill
Nathan M. Merrill
SKSamuel D. Kaffenberger
Samuel D. Kaffenberger
LBLiwei Bao
Liwei Bao
NVNathalie Vandecan
Nathalie Vandecan
LGLaura Goo
Laura Goo
AUAaron M. Udager
Aaron M. Udager

21 June 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
AMAki Morikawa
Aki Morikawa
JLJinju Li
Jinju Li
PUPeter Ulintz
Peter Ulintz
XCXu Cheng
Xu Cheng
AAAthena Apfel
Athena Apfel
NMNathan Merrill
Nathan Merrill
The development of novel therapies for brain metastases is an unmet need. Brain metastases may have unique molecular features that could be explored as therapeutic targets. A better understanding of the drug sensitivity of live cells coupled to molecular analyses will lead to a rational prioritization of therapeutic candidates. We evaluated the molecular profiles of 12 breast cancer brain metastases (BCBM) and matched primary breast tumors to identify potential therapeutic targets. We established six novel patient-derived xenograft (PDX) from BCBM from patients undergoing clinically indicated surgical resection of BCBM and used the PDXs as a drug screening platform to interrogate potential molecular targets. Many of the alterations were conserved in brain metastases compared with the matched primary. We observed differential expressions in the immune-related and metabolism pathways. The PDXs from BCBM captured the potentially targetable molecular alterations in the source brain metastases tumor. The alterations in the PI3K pathway were the most predictive for drug efficacy in the PDXs. The PDXs were also treated with a panel of over 350 drugs and demonstrated high sensitivity to histone deacetylase and proteasome inhibitors. Our study revealed significant differences between the paired BCBM and primary breast tumors with the pathways involved in metabolisms and immune functions. While molecular targeted drug therapy based on genomic profiling of tumors is currently evaluated in clinical trials for patients with brain metastases, a functional precision medicine strategy may complement such an approach by expanding potential therapeutic options, even for BCBM without known targetable molecular alterations. Significance: Examining genomic alterations and differentially expressed pathways in brain metastases may inform future therapeutic strategies. This study supports genomically-guided therapy for BCBM and further investigation into incorporating real-time functional evaluation will increase confidence in efficacy estimations during drug development and predictive biomarker assessment for BCBM.

24 June 2026 in Research Square
Verified
Preprint
Open access
PDF file
CKCarl Koschmann
Carl Koschmann
KSKallen Schwark
Kallen Schwark
KWKelsey Wink
Kelsey Wink
ACAntonella De Cola
Antonella De Cola
MMMadeline Miclea
Madeline Miclea
JCJean-Philippe Coppe
Jean-Philippe Coppe
PDGFRA alterations define a high-risk subset of high-grade glioma (HGG), yet targeted therapies have yielded limited and transient benefit. Here, we show that the CNS-penetrant PDGFRA inhibitor avapritinib induces sustained MAPK pathway activation at supratherapeutic dosing, revealing a therapy-induced adaptive vulnerability. High-dimensional kinome profiling (>900 nodes) and in vivo studies demonstrate robust, dose-dependent ERK activation following avapritinib treatment. This response is enriched in cycling oligodendrocyte precursor cell-like (OPC-like) tumor populations and promotes survival through ERK-dependent stabilization of the anti-apoptotic protein MCL-1. Modeling of clinically relevant PDGFRA variants reveals that D842V-mutant tumor cells exhibit heightened MAPK activation and potential for MAPK co-targeting. Rational combination strategies suppress this adaptive signaling, with MEK inhibition producing durable pathway suppression and significant survival benefit in vivo. Translation to patients demonstrates feasibility and early clinical activity, including a sustained complete regression in an unresected PDGFRA-mutant HGG treated with avapritinib and the MEK1/2 inhibitor selumetinib. Together, these findings identify adaptive MAPK reactivation as a targetable liability and support combined PDGFRA–MAPK inhibition as a therapeutic strategy.

12 June 2026
Verified
Other
Open access
XCXiaoqing Cheng
Xiaoqing Cheng
KPKhooshbu K. Patel
Khooshbu K. Patel
BZBrandon Zhou
Brandon Zhou
YFYiwei Fu
Yiwei Fu
RCRyan T. Cleary
Ryan T. Cleary
RBRon Bose
Ron Bose
Table S3 from Interleukin-34–Induced Arg1+ Macrophages Play a Key Role in Breast Cancer Brain Metastasis

12 June 2026
Verified
Other
Open access
XCXiaoqing Cheng
Xiaoqing Cheng
KPKhooshbu K. Patel
Khooshbu K. Patel
BZBrandon Zhou
Brandon Zhou
YFYiwei Fu
Yiwei Fu
RCRyan T. Cleary
Ryan T. Cleary
RBRon Bose
Ron Bose
Spatial feature plot of macrophage markers and related chemokines and cytokines.

12 June 2026
Verified
Other
Open access
XCXiaoqing Cheng
Xiaoqing Cheng
KPKhooshbu K. Patel
Khooshbu K. Patel
BZBrandon Zhou
Brandon Zhou
YFYiwei Fu
Yiwei Fu
RCRyan T. Cleary
Ryan T. Cleary
RBRon Bose
Ron Bose
Brain metastases occur in up to 40% of patients with stage IV breast cancer, and the cerebellum is a common site for metastases in HER2-positive breast cancer. We developed a syngeneic, immunocompetent mouse model of breast cancer brain metastases (BCBM) by stereotactically injecting murine breast cancer organoids into the cerebellum. Spatial transcriptomics on these brain metastases revealed that breast cancer cells produce interleukin-34 (IL34), which induces ARG1+ macrophages at the invading edge of metastases. IL34 expression in human brain metastasis samples was measured in two independent datasets, and IL34 was expressed widely in both HER2+ and HER2− human BCBM. Remarkably, IL34-deficient breast cancer cells failed to establish tumors in the mouse cerebellum. Furthermore, treatment with a blocking antibody against the IL34 receptor, CSF1R, led to tumor shrinkage, highlighting the translational potential of these findings, as a CSF1R-blocking antibody is FDA-approved for another indication, graft-versus-host disease.Significance:Targeting IL34–CSF1R is a potential new approach to treat BCBM and could be combined with existing therapies. IL34 expression is widely found in human BCBM.